Dissecting Therapeutic Resistance to ERK Inhibition
暂无分享,去创建一个
L. Zawel | S. Fawell | L. Jayaraman | E. Morris | A. Samatar | A. Hruza | S. Jha | C. Restaino | P. Dayananth | A. Cooper | S. Black | N. Elsen | M. Mansueto | J. Arbanas | D. McMasters | G. Schroeder | A. Mannarino | Stuart Black
[1] A. Pardi,et al. Slow inhibition and conformation selective properties of extracellular signal-regulated kinase 1 and 2 inhibitors. , 2015, Biochemistry.
[2] S. Knapp,et al. A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics , 2014, Nature chemical biology.
[3] T. Graeber,et al. Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma , 2014, Molecular Cancer.
[4] A. Shaw,et al. Molecular Pathways Molecular Pathways : Resistance to Kinase Inhibitors and Implications for Therapeutic Strategies , 2014 .
[5] G. Pupo,et al. BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact , 2014, Clinical Cancer Research.
[6] Shuxia Zhao,et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. , 2013, Cancer discovery.
[7] M. Gore,et al. Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. , 2013, Cancer discovery.
[8] P. Shapiro,et al. Structure of extracellular signal-regulated kinase 2 in complex with ATP and ADP. , 2012, Acta crystallographica. Section F, Structural biology and crystallization communications.
[9] K. Flaherty,et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.
[10] A. Hauschild,et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.
[11] J. Utikal,et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. , 2012, The New England journal of medicine.
[12] Matthew J. Davis,et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma , 2012, Nature Genetics.
[13] Dirk Schadendorf,et al. Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group , 2012 .
[14] T. Gilmer,et al. Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations , 2012, Molecular Cancer Therapeutics.
[15] Mari Mino-Kenudson,et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. , 2012, Cancer discovery.
[16] S. Nelson,et al. Melanoma whole exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance , 2012, Nature Communications.
[17] Tom Misteli,et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) , 2011, Nature.
[18] N. Rosen,et al. Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation. , 2011, Cancer research.
[19] Nikhil Wagle,et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] A. Ribas,et al. Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition. , 2011, Cancer research.
[21] A. Hauschild,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.
[22] A. Fernández-Medarde,et al. Ras in cancer and developmental diseases. , 2011, Genes & cancer.
[23] A. Iafrate,et al. BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation , 2010, Science Signaling.
[24] W. Sellers,et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition , 2009, Proceedings of the National Academy of Sciences.
[25] K. Resing,et al. The gatekeeper residue controls autoactivation of ERK2 via a pathway of intramolecular connectivity , 2006, Proceedings of the National Academy of Sciences.
[26] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[27] A. Adjei,et al. Blocking oncogenic Ras signaling for cancer therapy. , 2001, Journal of the National Cancer Institute.
[28] E. Goldsmith,et al. Phosphorylation of MAP Kinases by MAP/ERK Involves Multiple Regions of MAP Kinases* , 1999, The Journal of Biological Chemistry.
[29] Elizabeth J. Goldsmith,et al. Atomic structure of the MAP kinase ERK2 at 2.3 Å resolution , 1994, Nature.
[30] Antoni Ribas,et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. , 2014, Cancer discovery.
[31] A. McKenna,et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. , 2014, Cancer discovery.
[32] P. Emsley,et al. Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.